BIOCON Latest Share Price (BIOCON)
TODAY IN ONE LINE
BIOCON fell 1.1% on average volume, lagging Nifty's 0.1% move, supported by recent strong earnings.
With a market cap of ₹64,739.6 Cr., it trades at a P/E of 119.79. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
BIOCON flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 594.3% and Profit up 162.1%
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 72.5% YoY
- ●Poor Capital ReturnsLow ROE of 1.0%
- ●Expensive ValuationTrading at a high P/E ratio of 175.5x
- ●Promoter SellingPromoter holding decreased by 0.17% QoQ
Latest BIOCON News
What changed recently?
Recent events, corporate actions, and announcements.
BIOCON valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for BIOCON, framed against the sector median so the premium or discount is obvious at a glance.
BIOCON trades at a P/E of 119.79× and P/B of 1.91×, against the Healthcare sector median P/E of 41.28×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
BIOCON technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BIOCON — derived from the latest tape, not yesterday's close.
BIOCON last traded at ₹397.4 with an intraday range of ₹396.2–₹404.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹397.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 420.20 | +22.80 | +5.74% |
| R3 | 411.50 | +14.10 | +3.55% |
| R2 | 408.20 | +10.80 | +2.72% |
| R1 | 402.80 | +5.40 | +1.36% |
| PIVOT | 399.50 | 2.10 | 0.53% |
| CURRENT | 397.40 | — | — |
| S1 | 394.10 | -3.30 | -0.83% |
| S2 | 390.80 | -6.60 | -1.66% |
| S3 | 385.40 | -12.00 | -3.02% |
| S4 | 376.70 | -20.70 | -5.21% |
BIOCON is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹401.2–₹404.55
Trading Below opening range, showing Bearishness
BIOCON financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for BIOCON — consolidated or standalone — with margins, YoY growth and key ratios inline.
BIOCON reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹64,739.6 Cr. and reported EPS of ₹0.87.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 15,262 | 16,927 ▲ 10.9% |
| Sales Growth YoY %Derived | 3.43% | 10.91% |
| Other Income | 1,208 | 343 ▼ 71.7% |
| Total Income | 16,470 | 17,270 ▲ 4.9% |
| 5,198 | 5,691 ▲ 9.5% | |
| Gross ProfitDerived | 10,064 | 11,236 ▲ 11.6% |
| Gross Margin %Derived | 65.94% | 66.38% |
| 6,898 | 7,781 ▲ 12.8% | |
| EBITDA (Operating Profit)Derived | 3,166 | 3,455 ▲ 9.1% |
| OPM %Derived | 20.75% | 20.41% |
| 2,681 | 2,544 ▼ 5.1% | |
| Profit Before Tax (PBT) | 1,887 | 448 ▼ 76.3% |
| 457 | 79 ▼ 82.7% | |
| Effective Tax %Derived | 24.23% | 17.66% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 1,429 | 369 ▼ 74.2% |
| Less: Non-controlling Interests | 416 | -17 ▼ 104.0% |
| Net Profit (Owner's PAT)Derived | 1,013 | 386 ▼ 61.9% |
| Net Profit Margin %Derived | 6.64% | 2.28% |
| PAT Growth YoY %Derived | -0.90% | -61.95% |
| Earnings Per Share (EPS ₹) | 8.44 | 2.38 ▼ 71.8% |
| Diluted Shares Outstanding (Cr) | 120 | 162 ▲ 35.0% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | 437 | 2,044 ▲ 368.1% |
| Total Expenses (incl. D&A & Interest) | 14,583 | 16,822 ▲ 15.3% |
| Material Cost % of RevenueDerived | 28.02% | 31.18% |
| Employee Cost % of RevenueDerived | 20.60% | 20.72% |
| Other Cost % of RevenueDerived | 24.59% | 25.24% |
| Interest Coverage (x)Derived | 1.65x | 1.51x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 5,514 | 6,367 ▲ 15.5% | 7,106 ▲ 11.6% | 8,184 ▲ 15.2% | 11,174 ▲ 36.5% | 14,756 ▲ 32.1% | 15,262 ▲ 3.4% | 16,927 ▲ 10.9% | |
| Sales Growth YoY %Derived | — | 15.46% | 11.60% | 15.17% | 36.54% | 32.05% | 3.43% | 10.91% | |
| Other Income | 144 | 161 ▲ 11.8% | 255 ▲ 57.7% | 213 ▼ 16.4% | 376 ▲ 76.7% | 866 ▲ 130.2% | 1,208 ▲ 39.6% | 343 ▼ 71.7% | |
| Total Income | 5,659 | 6,529 ▲ 15.4% | 7,360 ▲ 12.7% | 8,397 ▲ 14.1% | 11,550 ▲ 37.6% | 15,621 ▲ 35.2% | 16,470 ▲ 5.4% | 17,270 ▲ 4.9% | |
1,897 | 2,052 ▲ 8.2% | 2,209 ▲ 7.6% | 2,718 ▲ 23.1% | 3,663 ▲ 34.8% | 4,898 ▲ 33.7% | 5,198 ▲ 6.1% | 5,691 ▲ 9.5% | ||
| Gross ProfitDerived | 3,618 | 4,315 ▲ 19.3% | 4,897 ▲ 13.5% | 5,466 ▲ 11.6% | 7,511 ▲ 37.4% | 9,858 ▲ 31.2% | 10,064 ▲ 2.1% | 11,236 ▲ 11.6% | |
| Gross Margin %Derived | 65.61% | 67.77% | 68.92% | 66.78% | 67.22% | 66.81% | 65.94% | 66.38% | |
2,224 | 2,712 ▲ 21.9% | 3,245 ▲ 19.6% | 3,495 ▲ 7.7% | 4,999 ▲ 43.0% | 6,559 ▲ 31.2% | 6,898 ▲ 5.2% | 7,781 ▲ 12.8% | ||
| EBITDA (Operating Profit)Derived | 1,394 | 1,603 ▲ 15.0% | 1,653 ▲ 3.1% | 1,970 ▲ 19.2% | 2,512 ▲ 27.5% | 3,299 ▲ 31.3% | 3,166 ▼ 4.0% | 3,455 ▲ 9.1% | |
| OPM %Derived | 25.27% | 25.18% | 23.26% | 24.07% | 22.48% | 22.36% | 20.75% | 20.41% | |
713 | 685 ▼ 4.0% | 785 ▲ 14.7% | 771 ▼ 1.9% | 1,241 ▲ 61.0% | 2,532 ▲ 104.0% | 2,681 ▲ 5.9% | 2,544 ▼ 5.1% | ||
| Profit Before Tax (PBT) | 1,214 | 1,215 ▲ 0.1% | 1,147 ▼ 5.6% | 1,190 ▲ 3.8% | 1,064 ▼ 10.6% | 1,609 ▲ 51.2% | 1,887 ▲ 17.2% | 448 ▼ 76.3% | |
212 | 315 ▲ 48.4% | 222 ▼ 29.7% | 212 ▼ 4.5% | 254 ▲ 20.1% | 227 ▼ 10.5% | 457 ▲ 101.1% | 79 ▼ 82.7% | ||
| Effective Tax %Derived | 17.49% | 25.94% | 19.31% | 17.77% | 23.88% | 14.13% | 24.23% | 17.66% | |
| Profit/Loss from Discontinued Ops | — | — | -10 | — ▲ 100.0% | — | — | — | — | |
| Total Profit for Period | 1,003 | 871 ▼ 13.1% | 846 ▼ 2.8% | 772 ▼ 8.8% | 643 ▼ 16.7% | 1,298 ▲ 101.8% | 1,429 ▲ 10.1% | 369 ▼ 74.2% | |
| Less: Non-controlling Interests | 97 | 123 ▲ 26.1% | 106 ▼ 13.9% | 123 ▲ 16.6% | 180 ▲ 46.3% | 275 ▲ 52.7% | 416 ▲ 51.1% | -17 ▼ 104.0% | |
| Net Profit (Owner's PAT)Derived | 905 | 748 ▼ 17.4% | 741 ▼ 1.0% | 648 ▼ 12.4% | 463 ▼ 28.6% | 1,023 ▲ 121.0% | 1,013 ▼ 0.9% | 386 ▼ 61.9% | |
| Net Profit Margin %Derived | 16.42% | 11.75% | 10.42% | 7.92% | 4.14% | 6.93% | 6.64% | 2.28% | |
| PAT Growth YoY %Derived | — | -17.35% | -1.03% | -12.44% | -28.64% | 120.99% | -0.90% | -61.95% | |
| Earnings Per Share (EPS ₹) | 7.54 | 6.24 ▼ 17.2% | 6.17 ▼ 1.1% | 5.40 ▼ 12.5% | 3.85 ▼ 28.7% | 8.52 ▲ 121.3% | 8.44 ▼ 0.9% | 2.38 ▼ 71.8% | |
| Diluted Shares Outstanding (Cr) | 120 | 120 ▲ 0.0% | 120 ▲ 0.0% | 120 ▲ 0.1% | 120 ▲ 0.0% | 120 ▲ 0.0% | 120 ▲ 0.0% | 162 ▲ 35.0% | |
| Share of Profit from Associates/JVs | 1 | -29 ▼ 3311.1% | -70 ▼ 140.5% | -207 ▼ 197.7% | -167 ▲ 19.3% | -84 ▲ 49.6% | — ▲ 100.0% | — | |
| Other Comprehensive Income (Net of Tax) | -72 | -188 ▼ 160.2% | 215 ▲ 213.9% | 110 ▼ 48.6% | 77 ▼ 30.5% | 387 ▲ 404.8% | 437 ▲ 12.9% | 2,044 ▲ 368.1% | |
| Total Expenses (incl. D&A & Interest) | 4,445 | 5,314 ▲ 19.5% | 6,213 ▲ 16.9% | 7,207 ▲ 16.0% | 10,486 ▲ 45.5% | 14,012 ▲ 33.6% | 14,583 ▲ 4.1% | 16,822 ▲ 15.3% | |
| Material Cost % of RevenueDerived | 35.90% | 34.04% | 34.20% | 34.38% | 28.56% | 34.37% | 28.02% | 31.18% | |
| Employee Cost % of RevenueDerived | 21.13% | 22.91% | 24.50% | 22.97% | 19.52% | 18.05% | 20.60% | 20.72% | |
| Other Cost % of RevenueDerived | 19.20% | 19.68% | 21.16% | 19.74% | 25.22% | 26.40% | 24.59% | 25.24% | |
| Interest Coverage (x)Derived | 13.34x | 16.19x | 16.25x | 17.10x | 3.34x | 1.78x | 1.65x | 1.51x |
BIOCON segment analysis : revenue and profit mix.
Disclosed business segments at BIOCON with their share of revenue and profit, switchable between consolidated and standalone reporting.
BIOCON discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for BIOCON.
Our AI distills the core fundamental drivers supporting BIOCON, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
BIOCON's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Quarterly sales growth 14.8% YoY demonstrates robust revenue momentum in latest quarter
Debt-to-equity ratio 0.0040x provides substantial financial flexibility for investments
Diversified portfolio across generics, biosimilars, and novel biologics reduces concentration risk
Established international presence in Brazil, Singapore, and other markets supports growth
Effectively debt-free balance sheet with minimal leverage enables strategic M&A optionality
Key Risks.
Latest quarterly EPS declined 63.5% YoY despite revenue growth, signaling profitability stress
TTM EPS declined 72.5% YoY, indicating severe earnings deterioration and valuation concerns
Quarterly profit variance -62.00% reflects extreme earnings volatility and operational instability
Net profit margin 2.29% TTM significantly below pharmaceutical industry peers, weak profitability
Operating cash flow negative -₹180.10 Cr (FY2026) from positive ₹621.10 Cr (FY2025); cash generation crisis
Flip Conditions.
Valuation risk. a P/E above 156 (~3.8× the sector multiple of 41.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
BIOCON peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BIOCON is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
BIOCON chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for BIOCON — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
BIOCON delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for BIOCON over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in BIOCON stood at 54.3% of traded volume, against a 20-day average of 53.5%.
BIOCON announcements: results, concalls, ratings, M&A.
Filings BIOCON sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
BIOCON files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 314 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Biocon Limited has informed the Exchange about Schedule of meet
General Updates
Biocon Limited has informed the Exchange about "Communication regarding remittance of final dividend for the FY 2025-26"
Updates
Biocon Limited has informed the Exchange regarding 'Company Statement'.
Updates
Biocon Limited has informed the Exchange regarding 'Company Statement'.
Analysts/Institutional Investor Meet/Con. Call Updates
Biocon Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Press Release
Credit Rating
Credit Rating
Credit Rating
Credit Rating
Credit Rating
BIOCON dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue BIOCON has declared, sequenced by announce and record date.
BIOCON corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About BIOCON: business, sector, key facts.
What BIOCON does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
BIOCON operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BIOCON, BSE: 532523.
Biocon Limited is a multinational biotechnology company headquartered in Bengaluru, India, with operations spanning across India, Brazil, Singapore, and other international markets. The company's core business revolves around the manufacturing and sale of a diverse range of biotechnology products, complemented by a robust research services arm. Their product portfolio caters to various therapeutic areas and spans across different stages of development, reflecting a vertically integrated business model.
The company's business is structured into four key segments: Generics, Novel Biologics, Biosimilars, and Research Services. The Generics segment focuses on the production and sale of generic formulations and active pharmaceutical ingredients (APIs). These generic offerings cover a wide therapeutic range, including anti-diabetic medications, immunosuppressants, treatments for multiple sclerosis, anti-cancer/oncology drugs, and various other therapeutic categories. This segment leverages economies of scale and established manufacturing capabilities to compete in the global generics market.
Biocon's Novel Biologics segment is dedicated to the development and commercialization of innovative biological therapies. A key focus here involves molecules targeting head and neck cancer, as well as promising pipeline products aimed at treating psoriasis. This segment represents Biocon's commitment to research and development, driving growth through the creation of novel therapies addressing unmet medical needs. The emphasis is on bringing first-in-class or best-in-class treatments to market, creating a potential for higher profit margins and market leadership.
The Biosimilars segment focuses on the development and commercialization of biosimilar products – essentially, lower-cost versions of existing biologic drugs. Biocon's portfolio in this area includes biosimilars of insulins, trastuzumab (Herceptin), pegfilgrastim (Neulasta), and bevacizumab (Avastin). This segment capitalizes on the growing demand for affordable biologic therapies, leveraging Biocon's manufacturing expertise and regulatory knowledge to compete effectively in a rapidly expanding market.
Finally, the Research Services segment provides comprehensive integrated discovery, development, and manufacturing services to a broad client base. This includes pharmaceutical companies, biotechnology firms, animal healthcare companies, consumer goods manufacturers, and even agrochemical companies. Offering a range of services enables Biocon to diversify its revenue streams, reduce reliance on any single product or therapeutic area, and leverage its expertise to generate additional income from its technological capabilities.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about BIOCON (BIOCON).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of BIOCON (BIOCON)?
The current share price of BIOCON (BIOCON) is ₹397.40. Today, the stock has declined by ₹4.60 (1.14%), trading in a range of ₹396.20 to ₹404.90. The stock opened at ₹404.00 with a trading volume of 31,08,555 shares.
02Is BIOCON stock a good investment for long-term?
BIOCON can be considered for long-term investment based on several factors. The company has a market capitalization of ₹64,739.6 Cr., P/E ratio of 119.79, ROE of 1.01%, and ROCE of 2.42%. The dividend yield stands at 0.13%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of BIOCON stock?
The 52-week high price of BIOCON (BIOCON) is ₹447.15, while the 52-week low is ₹337.05. Currently trading at ₹397.40, the stock is 17.91% above its 52-week low and 11.13% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy BIOCON stock at the current price?
Whether to buy BIOCON stock at ₹397.40 depends on multiple factors. The stock is currently trading with a P/E ratio of 119.79 and P/B ratio of 1.91. Today's performance shows a loss of 1.14%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of BIOCON and when is the next dividend?
BIOCON offers a dividend yield of 0.13%, which means for every ₹100 invested at the current price of ₹397.40, you can expect to receive approximately ₹0.13 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of BIOCON?
BIOCON's key financial metrics include: P/E Ratio: 119.79, P/B Ratio: 1.91, ROE: 1.01%, ROCE: 2.42%, Dividend Yield: 0.13%, EPS: ₹0.87, Book Value: ₹224.71, and Debt-to-Equity: 0.4. The company's market cap stands at ₹64,739.6 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is BIOCON stock performing today in the market?
BIOCON stock opened at ₹404.00 and is currently trading at ₹397.40, showing a decline of ₹4.60 (1.14%). The intraday high is ₹404.90 and low is ₹396.20. The trading volume stands at 31,08,555 shares, indicating strong market participation today.
08What is the P/E ratio of BIOCON and what does it indicate?
BIOCON has a Price-to-Earnings (P/E) ratio of 119.79, which means investors are willing to pay 119.79 for every ₹1 of earnings. With an EPS of ₹0.87, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about BIOCON (BIOCON) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.